Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A.

Nat Med. 2010 Oct;16(10):1134-40. doi: 10.1038/nm.2227. Epub 2010 Sep 26.

2.

MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

Slack A, Lozano G, Shohet JM.

Cancer Lett. 2005 Oct 18;228(1-2):21-7. Review.

PMID:
15927364
3.
4.

The MYCN oncoprotein as a drug development target.

Lu X, Pearson A, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):125-30. Review.

PMID:
12880971
5.

The p53 pathway and its inactivation in neuroblastoma.

Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):93-8. Review.

PMID:
12880966
6.

MYCN oncoprotein targets and their therapeutic potential.

Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA.

Cancer Lett. 2010 Jul 28;293(2):144-57. doi: 10.1016/j.canlet.2010.01.015. Epub 2010 Feb 13. Review.

PMID:
20153925
7.

The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.

Waters AM, Beierle EA.

Anticancer Agents Med Chem. 2014 Jan;14(1):46-51. Review.

PMID:
24041229
8.

Neuroblastoma models for insights into tumorigenesis and new therapies.

Kiyonari S, Kadomatsu K.

Expert Opin Drug Discov. 2015 Jan;10(1):53-62. doi: 10.1517/17460441.2015.974544. Epub 2014 Oct 25. Review.

PMID:
25345447
9.

Didymin: an orally active citrus flavonoid for targeting neuroblastoma.

Singhal SS, Singhal S, Singhal P, Singhal J, Horne D, Awasthi S.

Oncotarget. 2017 Apr 25;8(17):29428-29441. doi: 10.18632/oncotarget.15204. Review.

Supplemental Content

Support Center